tapebrief
PFE · Q2 2025

PFE · Q3 2025 Earnings

Bullish

Pfizer

Reported November 4, 2025

30-second summary

Revenue fell 6% YoY to $16.65B in Q3 with non-GAAP EPS of $0.87 and gross margin of 76.1%; management raised FY2025 adjusted EPS guidance to $3.00–$3.15 (from $2.90–$3.10) while reaffirming the $61–64B revenue band for the second consecutive quarter. The EPS raise is mechanically driven by a 200bps cut to the effective tax rate assumption (to ~11.0% from ~13.0%) and a $400M reduction in R&D spend at both ends of the range — not by top-line. The headline strategic event is Pfizer's aggressive legal posture against Novo Nordisk's competing bid for Metsera, which management called "illusory" and an antitrust violation.

Headline numbers

EPS

Q3 FY2025

$0.87

Revenue

Q3 FY2025

$16.65B

-6.0% YoY

Gross margin

Q3 FY2025

76.1%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$16.65B-6.0%$14.65B+13.7%
EPS$0.87—$0.78+11.5%
Gross margin76.1%—76.1%+0bps

Guidance

Pfizer raised full-year FY2025 Adjusted EPS guidance by $0.10–$0.05 (to $3.00–$3.15, up from $2.90–$3.10) and narrowed the range, while reaffirming revenue and reducing R&D/tax rate guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted Diluted EPS
FY2025
$2.90 to $3.10$3.00 to $3.15+$0.10 to +$0.05 (midpoint +$0.075)Raised
Adjusted R&D Expenses
FY2025
$10.4 to $11.4 billion$10.0 to $11.0 billion-$0.4 to -$0.4 (low and high end both reduced)Lowered
Effective Tax Rate on Adjusted Income
FY2025
Approximately 13.0%Approximately 11.0%-200 basis pointsLowered

Reaffirmed unchanged this quarter: Revenue ($61.0 to $64.0 billion), Adjusted SI&A Expenses ($13.1 to $14.1 billion)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Global Biopharmaceuticals Business (Biopharma)$16.31B-6.0%
Primary Care$7.646B-16.0%
Specialty Care$4.411B+1.0%
Oncology$4.253B+4.0%
Pfizer CentreOne (PC1)$0.344B+18.0%
Eliquis$2.015 billion—
Vyndaqel family$1.591 billion—
Ibrance$1.057 billion—
Prevnar family$1.742 billion—
Paxlovid$1.225 billion—
Comirnaty$1.151 billion—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
United States$10.691B-11.0%
Total International$5.963B+2.0%
Adjusted Diluted EPS Guidance FY2025$3.00 to $3.15—
Full-Year 2025 Revenue Guidance$61.0 to $64.0 billion—

Management tone

Narrative arc: Q2 LOE bridge confidence → Q3 cost program as offense → Q3 transformation delivery with M&A combat.

COVID went from "forecasted but unpredictable" last quarter to "substantially de-risked" this quarter. In Q2 management warned that the FY revenue reaffirmation depended on COVID volumes landing in H2; this quarter Dave Denton said "our adjusted diluted earnings per share guidance substantially de-risked the current lower than anticipated COVID trends." The shift signals that non-COVID is now outperforming plan enough to absorb softer COVID — a structurally different conviction than three months ago, when COVID was the swing factor for the FY guide.

Cost program rhetoric escalated from "margin lever" to "execution proven." Last quarter management framed the $7.2B-net / $7.7B-overall savings target as a forward commitment that would do more work than revenue. This quarter that program is being credited with absorbing both tariff impacts (China, Canada, Mexico, explicitly named) and a softer COVID quarter while still funding an EPS raise. The R&D guide cut of $400M is the first hard evidence the program is pulling forward, not just running on schedule.

Metsera language went from acquisition announcement to combat posture. Three months ago 3SBio and Metsera were standard tuck-in narratives within the $13B BD capacity Pfizer had flagged. This quarter Albert Bourla said of Novo's bid: "We believe that Novo Nordisk offer is illusory and cannot constitute a superior proposal under the terms of our merger agreement with Metsera, because it violates antitrust law and there is a high risk it will never be consummated." Pair that with Bourla calling FTC's early HSR termination "unprecedented during a government shutdown" — management is not negotiating, it's litigating. The shift signals high conviction in Metsera as the obesity entry point Pfizer cannot afford to lose, and explicit willingness to absorb 2030-dilutive economics to win it.

Government pricing agreement reframed from constraint to clearance. Last quarter Pfizer wouldn't quantify MFN/tariff impact and refused to discuss the July 31 Trump letter. This quarter Bourla called the U.S. government agreement a "landmark" that "removed uncertainty on two critical policy fronts," with Denton acknowledging "no impact on our 2025 guidance" and only a "dilutive impact to our 2026 financial outlook" (still unquantified). The tone shift — from defensive non-disclosure to positioning the deal as strategic clarity — suggests Pfizer has decided the policy uncertainty was a bigger drag than the price concession.

Next-gen PCV pushed out a year with conditional language. In Q2 the Phase 3 adult 25 program was a 2025 start. Now Bourla says "we are planning to start the study next year if the FDA aligns with our approach" and "pending positive data and regulatory feedback" for the pediatric program. The shift is meaningful: a pipeline asset slipped a year with explicit regulatory dependency language, in a vaccine franchise (Prevnar) where competition is closing.

Recurring themes management leaned on this quarter:

Non-COVID portfolio strength offsetting infectious disease declineOncology pipeline expansion and clinical validation (PADSE, BRAFTOVI/MECTOVI, 707 bispecific)Cardiometabolic repositioning through Metcera obesity franchise acquisitionManufacturing cost optimization driving margin expansion ($7.7B cumulative savings target by 2027)Strategic clarity from U.S. government pricing agreement reducing policy uncertaintyBusiness development focus on late-stage assets with long-term 2030+ revenue trajectory

Risks management surfaced:

COVID product demand decline from lower disease incidence and vaccination ratesMetcera acquisition antitrust risk and consummation uncertainty despite FTC HSR clearancePrevnar pediatric bulk order timing delays in U.S. government procurementRSV vaccine population activation challenges in third market season2026 financial impact from U.S. government pricing agreement (magnitude not quantified)

Q&A highlights

Vommel Devan · Guggenheim Securities

Questions on Vinda pricing and market share dynamics with new competition, and on PADSEV commercial uptake and expected impact of muscle invasive indication approval.

Management noted Vinda maintains statistically significant mortality and CV hospitalization benefits, once-daily dosing, and market share leadership despite new competition. Volume growth offset by IRA rebates and payer contracting. PADSEV performing as expected; noted 55% share in cisplatin-ineligible MIBC patients and potential 22,000-patient population expansion with MIBC indication.

Vinda: 90% access across U.S.PADSEV: 55% share among cisplatin ineligible patients, 45-50% among eligiblePADSEV MIBC potential market: ~22,000 patientsInventory adjustment in Q2 from dropship to wholesaler model for CGEN products

Dave Reisinger · Lazard Partners

Question on MetSERA legal process timeline and merits of Pfizer's antitrust arguments against Novo's acquisition.

Management declined to comment extensively due to pending litigation but reiterated that Novo's deal is illegal attempt to catch-and-kill an emerging competitor, leveraging foreign company status and government shutdown. Emphasized pursuing all legal resources.

Novo deal characterized as illegal antitrust violationDescribed as catch-and-kill strategy against emerging competitorForeign company attempting end-run around U.S. antitrust law

Assad Hader · Goldman Sachs

Questions on BD contingency plans if MetSERA fails, 2026 guidance pushes/pulls including Apex dynamics, and dilution from recent MFN deal.

Management indicated significant BD resources remain available for acquisitions across four therapeutic areas. Early to discuss 2026 guidance specifics but indicated MedCera and 3S Bio investments will have slightly dilutive effect on 2026 operating performance. Active efforts in China particularly, with team expansion.

MedCera and 3S Bio will have slightly dilutive effect to 2026 operating performanceIncreased China team sizeCompany has significant BD resources available2026 guidance to be provided by year-end

Courtney Breen · Bernstein

Question on factors that supported unprecedented early FTC termination of waiting period for MetSERA deal.

Management stated FTC made independent decision; noted it demonstrates strength of deal and pathway to clearance. Emphasized FTC concern about competitive conflict between Novo's dominant position and complete Metzera pipeline.

FTC granted early termination of waiting periodDemonstrates deal strength and rapid market pathway

Terrence Flynn · Morgan Stanley

Questions on LRExVO/Magnetism 5 trial delay to 2026 and comparison to J&J trial, and Paxlovid pricing dynamics.

Management noted Magnetism 5 is event-driven; timing could shift based on event occurrence (potentially positive if events delayed). No material price changes on Paxlovid; channel mix may vary.

Magnetism 5 expected to read out beginning 2026Study is event-driven and timing may shiftNo material Paxlovid price changes; possible channel mix variation

Answers to last quarter's watch list

FY revenue reaffirmation in Q3. Held — revenue guide reaffirmed at $61–64B for the second straight quarter. Comirnaty $1.15B and Paxlovid $1.23B printed in Q3, but management's "de-risked" language signals confidence the FY band lands even if Q4 COVID comes in softer than originally planned.
Resolved positively
MFN/tariff quantification. Partially answered. Management confirmed guidance "absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico" and disclosed the U.S. government pricing agreement has no 2025 impact but will be dilutive to 2026 (magnitude not quantified). Tariff sizing is implicitly inside the FY raise; the 2026 MFN drag is still a known unknown.
Continue monitoring
PADCEV muscle-invasive bladder cancer readout. Management characterized the MIBC indication as expanding the addressable population to ~22,000 patients with 55% share already in cisplatin-ineligible patients; explicit readout-timing language was not in the Q&A summary.
Continue monitoring
3SBio 707 Phase 3 program announcement. Not addressed substantively on this call — 707 was named as a key oncology asset in prepared themes but the Phase 3 program structure was not announced.
Not resolved
Net cost savings progress against $7.2B/$7.7B target. The R&D guide cut of $400M and tax rate cut of 200bps are the first hard evidence the program is pulling forward. The $7.2B-by-end-2027 target was explicitly reaffirmed in prepared remarks.
Resolved positively
Whether leverage stays at 2.7x or rises with a deal. Metsera and the Novo counter-bid have moved this from theoretical to live — management is explicitly defending a deal it called "slightly dilutive" through 2030. Capacity remains for further BD across four therapeutic areas.
Continue monitoring

What to watch into next quarter

Metsera resolution and Pfizer's response if Novo prevails. Management called Novo's bid "illusory" and said it would pursue all legal avenues. Watch whether Pfizer closes the deal at the announced price, raises its bid, or walks — and what BD pivot follows. The "slightly dilutive through 2030" framing is now the floor case if Pfizer wins.

2026 guidance framework at the year-end call. Management said full 2026 guide comes by year-end. Watch the magnitude of the MFN/U.S. government-agreement dilution disclosure, and whether the $61–64B-equivalent revenue base for 2026 grows, holds, or contracts.

Q4 COVID prints against the "substantially de-risked" framing. If Comirnaty and Paxlovid land materially below Q4 2024, the question becomes whether non-COVID outperformance was understated or whether FY revenue still lands inside the band.

Effective tax rate sustainability into 2026. The 200bps cut to ~11.0% drove essentially the entire EPS midpoint raise. If this is structural (geographic mix, IP planning) it persists; if it's one-time, 2026 EPS faces a built-in headwind.

Next-gen PCV Phase 3 starts in 2026. Management's "if the FDA aligns with our approach" and "pending positive data and regulatory feedback" language is a hedge that wasn't there last quarter. Watch for FDA alignment confirmation in the first half of 2026.

Sources

  1. Pfizer Q3 2025 Earnings Press Release (SEC EX-99): https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.